Rexahn Pharmaceuticals, Inc. Recap

What is your opinion of Rexahn Pharmaceuticals, Inc.?

Rexahn Pharmaceuticals, Inc.

AMEX:RNN - Oct. 14th 3:55am

$ 0.479 -0.001 (-0.21%)

Shares of Rexahn Pharmaceuticals, Inc. – a $85.8 million market cap Biotechnology & Medical Research company – have fallen -0.21 percent to $0.479 as of 12:00 AM.

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company has three clinical stage drug candidates in active development: Archexin, a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including colon, lung and pancreatic cancer, and Supinoxin (RX-5902), a small molecule that inhibits the phosphorylation of p68, which is expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation or tumor growth of cancer cells. The Company also has two drug candidates in pre-clinical development: Archexin-Nano and RX-21101.

Find out more about Rexahn Pharmaceuticals, Inc..

Rexahn Pharmaceuticals, Inc. Filed an SEC document

Rexahn Pharmaceuticals, Inc. (AMEX:RNN) filed an Important Updates, SEC DOC 8-K, on September 28th, 2015.

ROCKVILLE, MD | 2 weeks ago

Rexahn Pharmaceuticals, Inc.